Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

The BCI and patient goals help oncology nurses counsel patients on endocrine therapy use after 5 years, per Michelle Kirschner RN, MSN, ACNP, APRN-BC.

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship ...

Beyond cancer treatments, scans, and countless appointments, there is another critical factor in a patient’s well-being: ...

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.

Oncology nurses can help patients and families understand the expectations of pediatric brain cancer survival, says Kasey Rangan, MSN, CPNP-PC, CPHON.